A paediatric vaccination vector based on live attenuated measles vaccine.

Therapie

Unité des Virus Lents, CNRS URA 1930, Institut Pasteur, Paris, France.

Published: September 2005

Live attenuated RNA viruses make highly efficient vaccines. Among them, measles virus (MV) vaccine has been given to a very large number of children and shown to be highly effective and safe. MV vaccine induces a life-long immunity after a single or two low-dose injections. It is easily produced on a large scale in most countries and can be distributed at low cost. Reversion to pathogenicity has never been observed with this vaccine. Because of all these characteristics, MV vaccine might be a very promising vector to immunise children against both measles and other infectious agents, such as HIV or flaviviruses, in the developing world. In this article, we describe recent data that we obtained showing the capacity of recombinant Schwarz MVs to express proteins from human immunodeficiency or West Nile viruses, and to induce specific immune responses able, in the case of West Nile virus, to protect from an experimental challenge.

Download full-text PDF

Source
http://dx.doi.org/10.2515/therapie:2005029DOI Listing

Publication Analysis

Top Keywords

live attenuated
8
west nile
8
vaccine
5
paediatric vaccination
4
vaccination vector
4
vector based
4
based live
4
attenuated measles
4
measles vaccine
4
vaccine live
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!